Several endothelin receptor antagonists (ERAs) have been developed for the treatment of pulmonary arterial hypertension (PAH). Some of them have been related to clinical cases of hepatocellular injury (sitaxentan [SIT]) and/or cholestasis (bosentan [BOS]). We aimed to determine if ambrisentan (AMB) and macitentan (MAC), in addition to BOS and SIT, could potentially cause liver damage in man by use of human HepaRG cells. Our results showed that like BOS, MAC-induced cytotoxicity and cholestatic disorders characterized by bile canaliculi dilatation and impairment of myosin light chain kinase signaling. Macitentan also strongly inhibited taurocholic acid and carboxy-2',7'-dichlorofluorescein efflux while it had a much lower inhibitory effect on influx activity compared to BOS and SIT. Moreover, these three drugs caused decreased intracellular accumulation and parallel increased levels of total bile acids (BAs) in serum-free culture media. In addition, all drugs except AMB variably deregulated gene expression of BA transporters. In contrast, SIT was hepatotoxic without causing cholestatic damage, likely via the formation of reactive metabolites and AMB was not hepatotoxic. Together, our results show that some ERAs can be hepatotoxic and that the recently marketed MAC, structurally similar to BOS, can also cause cholestatic alterations in HepaRG cells. The absence of currently known or suspected cases of cholestasis in patients suffering from PAH treated with MAC is rationalized by the lower therapeutic doses and C max , and longer receptor residence time compared to BOS.
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by hypertension in pulmonary arteries with an estimated prevalence of 15-50 cases per million annually (Peacock et al., 2007) . The median survival for an untreated PAH patient with supportive care is 2.8 years after diagnosis and the overall prognosis remains guarded (D'Alonzo et al., 1991; Velayati et al., 2016) . The pathogenesis of this disease is marked by enhanced synthesis of endothelin-1 (ET-1) and progressive proliferation and hypertrophy of smooth muscle cells in the pulmonary vasculature (Dupuis and Hoeper, 2008) . Endothelin receptor antagonists (ERAs) are thought to offer appropriate treatment. They have the capacity to inhibit the binding of endothelin, a strong vasoconstrictive peptide, to its receptors on smooth muscle cells which results in a vasodilation in order to decrease the pulmonary vascular pressure (Humbert et al., 2004) . Endothelin receptor antagonists have been shown to improve exercise tolerance and slow progression of disease in PAH patients (McLaughlin et al., 2011) . Two ERAs are currently approved in the United States under the name of bosentan (BOS) in 2001 and ambrisentan (AMB) in 2007. Another agent, sitaxentan (SIT), was approved in 2006 in Europe but not in the United States. Finally, a new ERA, macitentan (MAC), received approval in 2013. These ERAs have been differently associated with liver injury. In 2010, SIT was removed from the market due to concerns about its liver toxicity (Galiè et al., 2011) and BOS was found to cause at least 3-fold upper limit of normal elevation of liver aminotransferases in about 16.8% of patients accompanied by elevated bilirubin in a small number of cases during clinical studies (Fattinger et al., 2001) . In contrast, AMB did not appear to cause hepatotoxicity with long-term treatment (Ben-Yehuda et al., 2012) . Although structurally similar to BOS, MAC has not been reported to cause elevation of liver transaminases or bilirubin. There is no data indicating that it has superior therapeutic potency to AMB (Sood, 2014) . The 4 ERAs differ in their level of action on the 2 different ET-1 receptors, endothelin A receptor (ET A ) and endothelin B receptor (ET B ), which are G protein-coupled receptors whose activation results in elevation of intracellular free calcium (Davenport and Battistini, 2002) . While MAC and BOS are dual antagonists, AMB and SIT are selective of ET A (Dupuis and Hoeper, 2008) . Ambrisentan is a propionic acid and the three others are sulfonamides. Bosentan, MAC, and SIT are direct inhibitors of the ATP binding cassette bile salt export pump (BSEP/ABCB11) as shown by using cells expressing human BSEP (Dawson et al., 2012; Fattinger et al., 2001; Lepist et al., 2014) . In contrast, MAC and its active metabolite ACT-132577 (Sidharta et al., 2011) were reported to have no significant inhibitory effects on bile salt transport in vivo (Bolli et al., 2012; Raja, 2010) . In vitro studies suggest that hepatic disposition of MAC is mainly driven by passive diffusion rather than organic anion transporting polypeptide (OATP)-mediated uptake (Bruderer et al., 2012) . Mechanisms of ERAs hepatotoxicity remain poorly understood. Recently, we demonstrated that BOS and other cholestatic drugs cause alterations of bile canaliculi (BC) dynamics coupled with impairment of the RhoA/Rho-kinase/myosin light chain kinase (ROCK/ MLCK) signaling pathway Sharanek et al., 2016) . Interestingly, ERAs act by reducing myosin-actin interactions and myosin II contractile activity in smooth muscle and nonmuscle cells through phosphorylation of the myosin light chain by both ROCK and Ca 2þ /calmodulin (CaM)-dependent MLCK (Dupuis and Hoeper, 2008; Miao et al., 2002) .
In the present work, we aimed to determine whether ERAs other than BOS are potentially cholestatic and to analyze the mechanisms involved in cytotoxic and cholestatic effects induced by the ERAs using human HepaRG cells. Our results showed that BOS and MAC shared in in vitro comparable cytotoxic and cholestatic properties while SIT was only cytotoxic and AMB was not hepatotoxic.
MATERIALS AND METHODS
Reagents. Macitentan and SIT were purchased from Alsachim (Illkirch-Graffenstaden, France Cell cultures and treatments. HepaRG cells were seeded at a density of 2.6 Â 10 4 cells/cm 2 in Williams' E medium supplemented with 2 mM glutaMAX, 100 U/ml penicillin, 100 lg/ml streptomycin, 10% Hyclone bovine fetal calf serum, 5 lg/ml insulin, and 50 lM hydrocortisone hemisuccinate. At confluence, after 2 weeks, HepaRG cells were transferred to the same medium supplemented with 1.7% dimethyl sulfoxide (DMSO) for 2 additional weeks in order to obtain confluent differentiated cultures containing nearly equal proportions of hepatocyte-like and progenitors/primitive biliary-like cells (Cerec et al., 2007) . These differentiated hepatic cell cultures were used for analytical assays. For drug treatments, differentiated HepaRG cells were incubated in a medium containing 2% serum and 1% DMSO. The list and characteristics of the 4 tested compounds are displayed in Table  1 and Supplementary Table 3 .
Cell viability. Cytotoxicity of the test compounds was evaluated using the MTT colorimetric assay. Briefly, cells were seeded in 24-well plates and exposed to various concentrations of each compound in triplicate for 24 h. After medium removal, 100 ll of serum-free medium containing MTT (0.5 mg/ml) was added to each well and incubated for 2 h at 37 C. The water-insoluble formazan was dissolved in 100 ll DMSO and absorbance was measured at 550 nm (Aninat et al., 2006) . IC20 values (the concentrations causing 20% cytotoxicity) were calculated from the concentration-responses curves.
Time-lapse cell imaging. Phase-contrast images of HepaRG cells were captured every 10 min, using time-lapse phase-contrast videomicroscopy. The inverted microscope Zeiss Axiovert 200M was equipped with a thermostatic chamber (37 C and 5% CO 2 )
to maintain the cells under normal culture conditions and an Axiocam MRm camera with a 20Âobjective.
Determination of bile canalicular lumen surfaces. Bile canalicular lumen surfaces appeared bright (white) and the hepatocytes/ biliary cells denser (black) using a phase-contrast microscope Zeiss Axiovert 200M. Brightness parameters were adjusted to eliminate noncorresponding objects and analysis was performed on at least 4 images per each condition (well). White canalicular lumen was then quantified using ImageJ software 1.48 every 10 min for 24 h. Data obtained during the first 4 h with all tested compounds are presented and BC quantification is expressed as percent of the control .
Myosin light chain kinase implication. Myosin light chain kinase implication was estimated using CaM, a specific MLCK activator , at a 5 mM final concentration either alone (control) or in cotreatment with the dilatators (ie, BOS and MAC). Bile canaliculi alteration was quantified after both drug treatment and drug/CaM cotreatment as described above.
Immunolabeling. Cells were washed with warm phosphate buffered saline (PBS), fixed with 4% paraformaldehyde for 20 min at room temperature, and then washed three times with cold PBS. After paraformaldehyde fixation, cells were permeabilized for 20 min with 0.3% Triton in PBS followed by 1-h incubation in PBS containing 1% bovine serum albumin and 5% normal donkey serum. Cells were then incubated overnight with primary antibodies directed against ZO-1, MRP2 (MRP2/ABCC2) and MRP3 (MRP3/ABCC3), and washed with cold PBS before 2-h incubation with mouse or rabbit Alexa fluor 488 labeled secondary antibodies in the same buffer as described above. Cells were washed with cold PBS and incubated with rhodaminephalloidin fluoprobe SR101 (200 U/ml) diluted at 1/100 for F-actin labeling for 20 min (Pernelle et al., 2011 the 4 drugs for 2 or 24 h followed by incubation with radiolabeled TCA for 30 min. Cells were then washed with PBS and lysed with 0.1 N NaOH. Accumulation of radiolabeled substrate was determined through scintillation counting (Anthé rieu et al., 2013).
[ 3 H]-TCA clearance was determined based on its accumulation in the cell layers (cells þ BC) and calculated relative to the control using the following formula: .
Real-time quantitative polymerase chain reaction analysis. Total RNA was extracted from 10 6 HepaRG cells with the SV total RNA isolation system (Promega, Charbonnieres-les-Bains, France). RNAs were reverse-transcribed into cDNA and real-time quantitative polymerase chain reaction (RT-qPCR) was performed using a SYBR Green mix. Primer pair sequences are listed here: GAPDH (ID 2597), forward, 5 0 -ttcaccaccatggagaaggc-
NTCP (ID 6554), forward, 5 0 -gggacatgaacctcagatt-3 0 : reverse, 
The list of compounds, their affinity to the 2 endothelin receptors, C max (mM), half-lives, dosing, clinical hepatic effects, and some results obtained in vitro with either vesicles overexpressing human BA transporters (*) or liver cells (**) are displayed. C max values and in vitro results are from the literature (see references).
Western blotting analysis of p-myosin light chain subunit-2. HepaRG cells were treated with the tested compounds for 1, 2, and 3 h at 100 mM where BC alteration occurred, then washed with cold PBS and finally resuspended in cell lysis buffer supplemented with protease and phosphatase inhibitors (Roche, Mannheim, Germany). Aliquots containing equivalent total protein content, as determined by the Bradford procedure with bovine serum albumin as the standard, were subjected to sodium dodecyl sulfate/12% polyacrylamide gel electrophoresis, electrotransferred to immobilon-p membranes, and incubated overnight with primary antibodies directed against p-myosin light chain subunit-2 (MLC2) and HSC70. After using a horseradish peroxidase conjugated anti-mouse/rabbit antibody (Thermo-Fisher Scientific, Waltham, Massachusetts), membranes were incubated with a chemiluminescence reagent (Millipore, Billerica, Massachusetts) and bands were visualized and quantified by densitometry with fusion-CAPT software (Vilber Lourmat, Collé gien, France).
Measurement of endogenous bile acid content. In order to avoid any bile acid (BA) contamination from the serum, all treatments and washings were done in serum-free media. Both dried cell pellets and 1 ml medium samples were collected for BA analysis from HepaRG cell cultures exposed to different drug concentrations at various time points. The BA content was measured using ultra high-pressure liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS). An Acquity UPLC BEH Waters column (Waters Corporation, Milford, Massachusetts), thermostated at 65 C, was used for chromatographic separation of BA. Mobile phases consisted of (A) (0.1% HCOOH in purified water) and (B) (0.05% triethylamine in acetonitrile) at 95:5 (v/v). Bile acids were eluted by increasing B/A ratio from 5 to 95 (v/v) for 14.5 min. Separation was achieved at a flow rate of 0.35 ml/ min for 18 min. Mass spectra were obtained using an API4000 SCIEX (AB-Sciex, Framingham, Massachusetts). Data were acquired by Software Analyst (ABSCIEX) V 1.6.1; Software Masslynx (Waters) V 4.1 and Software Watson (Thermo-Fisher scientific) V 7.3.0.01. The amount of individual BAs in each medium sample was calculated as pmol/ml (nM) and in cell lysate samples as pmol and scaled per mg of proteins. Because basal primitive biliary cells do not express BAs metabolizing enzymes as well as BA transporters they were neglected for calculation of BA synthesis. Only HepaRG hepatocytes were considered and estimated to represent 50% of total cells in HepaRG cell cultures (Cerec et al., 2007) . Total cholic acid (CA) represented the sum of (unconjugated CA þ TCA þ GCA) whereas total chenodeoxycholic acid (CDCA) represented the sum of (unconjugated CDCA þ TCDCA þGCDCA). 
RESULTS

Cytotoxic Potential of ERAs
Preliminary experiments were performed to calculate IC20 values for the 4 drugs after a 24-h treatment of HepaRG cells with a range of drug concentrations from 0 to 800 mM using the MTT assay ( Figure 1A ). The most cytotoxic compound was BOS with an IC20 value of 120 mM followed by MAC (230 mM) and SIT (580 mM). Ambrisentan was not cytotoxic in the range of concentrations tested. In order to determine whether cytotoxicity was related to cytochrome P450 (CYP)-mediated formation of toxic metabolites a set of cultures was cotreated with ERAs and 300 mM 1-ABT, a nonselective inhibitor of human P450s, for 24 h. Cotreatment with ABT markedly reduced SIT and BOS cytotoxicity at high concentrations (ie, at 400 and 800 mM, respectively) ( Figure 1B ) while it did not alter effects of MAC.
Bosentan and Macitentan Caused Morphological Alterations of Bile Canaliculi
We have previously shown that cholestatic drugs cause constriction or dilatation of BC after a short treatment of HepaRG cells Sharanek et al., 2016) . In the present study, we analyzed effects of ERAs on BC dynamics over a 4-h period using time-lapse videomicroscopy imaging. Macitentan and BOS induced dilatation of BC, starting within the first hour whereas SIT and AMB did not affect BC dynamics (Figure 2A ) (Supplementary videos). Interestingly, even at 400 mM, corresponding to a cytotoxic concentration for both BOS and MAC, the two other ERAs, SIT, and AMB, did not affect BC dynamics ( Figure 2D ) (Supplementary videos). At 600 mM (ie, around IC20 value), SIT caused some morphological alterations without any change in BC structures ( Figure 2D ). Bile canaliculi alterations caused by BOS and MAC were quantified by measuring the canalicular surface using the ImageJ software every 10 min for 180 min BC dilatation was greater with MAC than with BOS ( Figure 2B ). Immunolocalization of the junctional zona occludens protein 1 (ZO-1) and pericanalicular F-actin did not evidence any obvious disruption of BC integrity associated with dilatation of the canalicular lumen at 2 h or longer treatments ( Figure 2C ).
Myosin Light Chain Subunit-2 and MLCK Impairment It has been postulated that dynamic movements of BC could be controlled by pericanalicular myosin activity . Treatment with BOS and MAC, the two drugs that induced BC dilatation, showed a decrease with time in MLC2 phosphorylation while AMB and SIT were ineffective ( Figures  3A and B) . Because MLCK is coupled to ROCK and shares MLC2 as a common substrate, we evaluated whether MLCK also contributed to BC lumen alterations. Myosin light chain kinase implication in BC deformations was determined by the use of CaM, a specific MLCK activator. HepaRG cells were treated with CaM in the presence of dilatators Sharanek et al., 2016) and BC alterations were quantified and compared to treatment with the modulator alone as described above. Cotreatment with 5 mM CaM partly counteracted dilatation induced by BOS and MAC while treatment with CaM 5 mM alone did not cause any effect on BC (Figures 3C and D) .
Bile Acid Profile Changes
Bile acid profiles were analyzed after treatment of HepaRG cells with 10, 50, and 100 mM of each drug for 4 or 24 h in serum-free medium. Interestingly, a dose-dependent intracellular decrease and parallel accumulation in supernatants of total BAs were observed with MAC, BOS, and SIT at both time points (Figure 4) . Ambrisentan did not cause any effect. At 100 mM MAC showed a decrease in BA intracellular accumulation dropping from 15.7 (control value) to 5 and 2 pmol/mg proteins, respectively, while BA content increased in the supernatant from 25 to 64 nM and 34 to 78 nM after 4 and 24 h treatment, respectively ( Figure 4C ).
Bosentan exhibited approximately the same pattern, ie, a decrease from 22 to 6 pmol/mg proteins in cellular layers and from 24 to 3 pmol/mg proteins after 4 and 24 h, respectively; in supernatants, values varied between 31 and 46 nM at 4 h and 51 and 67 nM at 24 h ( Figure 4B ). At 100 mM SIT showed a more important decrease in total BAs in cellular layers ranging from 15 to 4 pmol/mg proteins and 15 to 2 pmol/mg proteins after 4 and 24 h, respectively. Concomitantly, BAs concentrations in the supernatant increased from 39 to 69 nM and 54 to 78 nM at 4 and 24 h of treatment with this drug ( Figure 4D ). Finally, AMB had no effect on BAs intracellular accumulation (around 19 pmol/mg proteins) and supernatant levels (between 33 and 70 nM) at all tested concentrations and at the two treatment time points ( Figure 4A ). Changes were also estimated as Cytotoxicity was measured by the MTT colorimetric assay. Each point is the mean 6 SEM of three independent experiments. Data were considered as significantly different from the cells treated only with ABT when # P < .05. Data were considered as significantly different from the control when *P < .05. percentages in comparison with controls and individual BAs were measured. As shown in Supplementary Tables 1 and 2, all individual BAs have the same tendency to decrease in cellular layers and to increase in supernatants.
FIG. 2. Effects of drugs on bile canaliculi dynamics. (A) Phase
Effects on Taurocholic Acid Influx and Canalicular Efflux Activities
To confirm whether ERA-induced BC deformations were associated with alterations of BA transport, influx and efflux activities were measured using [ 3 H]-TCA as a substrate. As shown in
Figures 4E, G, and H, AMB had no significant effect on either influx or efflux activities. Macitentan and BOS inhibited TCA efflux, starting at 10 (13-76Â C max ) and 50 mM (7Â C max ) for MAC and BOS, respectively, whereas SIT activated efflux activity at low concentration (10 mM) and was ineffective at 50 mM and higher concentrations ( Figure 4E ). These concentrations represent 0.5Â and 2Â C max . To confirm its greater activity at 10 mM, SIT was also tested at 1, 5, and 20 mM. Intermediate increased values were obtained confirming the concentration-dependent ) and represent means 6 SEM of 3 independent experiments. One hour treatment was arbitrarily set at a fixed value of 2.5 for all drugs. Data were considered significantly different when *P < .05. (C, D) Cells treated with 100 mM BOS or MAC 6 5 mM CaM for 2 h. Phase-contrast images and BC surface quantification as described in Figure 2B . Arrows show BC dilatation. Bar ¼ 30 mM.
induction of TCA efflux by SIT, peaking at around 20 mM ( Figure  4F ). Taurocholic acid influx was inhibited by BOS and SIT; activity started to decrease with both drugs at 10 mM after 2 h treatment ( Figure 4G ). After 24 h SIT and BOS still exerted an inhibitory effect starting at 10 and 50 mM, respectively. Macitentan and AMB did not influence TCA influx ( Figure 4H ). Carboxy-2',7'-dichlorofluorescein Canalicular Accumulation Fluorescent CDF, predominantly excreted by MRP2, was also visualized in BC of untreated and treated HepaRG cells. While AMB did not show any significant effect compared to control cells, SIT, MAC, and BOS exerted an inhibition of CDF accumulation in the BC ( Figure 5 ).
Modulation of Bile Acid Transporters Gene Expression
Genes encoding the major BA transporters are also deregulated by cholestatic drugs (Pauli-Magnus and Meier, 2006). Six major genes encoding either efflux (BSEP, MRP2, MRP3, MRP4) or uptake (NTCP, OATP-B) transporters were analyzed by RT-qPCR after 4, 8, or 24 h treatment with 3 concentrations of each tested drug (ie, 10, 50, and 100 mM). Different patterns depending on the compound and the tested concentration were evidenced and are shown in Table 2 and Supplementary Figures 1-3 . Ambrisentan did not deregulate any of the transporters at the 3 concentrations used whatever the duration of treatment (4, 8, and 24 h). In contrast, variable effects were observed with the 3 other drugs. Bile salt export pump (BSEP) was strongly repressed by BOS starting at 8 h and by MAC only at high concentrations after 24 h (Table 2 ; Supplementary Fig. 2 ). Na þ -taurocholate cotransporting polypeptide (NTCP) was downregulated starting at 24 h for the two high concentrations (ie, 50 and 100 mM) of BOS, MAC, and SIT. Multidrug resistance-associated protein 2 (MRP2) was upregulated with MAC and SIT at the two highest concentrations (Table 2 ; Supplementary Fig. 1 ). Organic anion transporting polypeptide-B (OATP-B) and MRP3 were decreased only with BOS starting after 8 h at the highest concentrations (Table 2 ; Supplementary Figures 2 and 3 ) and MRP4 was not modulated by any of the drugs (Table 2 ; Supplementary Fig. 3) .
DISCUSSION
In the current work, we showed MAC shares similar cholestatic features with BOS while SIT exhibited only cytotoxic effects. In contrast, AMB showed no features of hepatotoxicity across the broad range of concentrations tested. Cytotoxicity of SIT and BOS observed in in vitro are supported by reports on hepatocellular injury in treated patients (Fattinger et al., 2001; Galiè et al., 2011; Lavelle et al., 2009) . Sitaxentan was found to induce hypertrophy and necrosis of centrilobular hepatocytes in dogs (Lin et al., 2012) , and to cause severe liver injury with 8 deaths during clinical trials (Owen et al., 2012) . Even though SIT was reported to inhibit BSEP activity in BSEPexpressing membrane vesicles (Morgan et al., 2013) , no clinical reports had shown its cholestatic potential. These false positive results could be related to the lack of metabolism in the vesicles. Indeed, SIT undergoes several enzymatic reactions with the involvement of various CYPs, including CYP2C9 and CYP3A4, that lead to a reactive ortho-quinone metabolite which is able to form adducts with glutathione (Erve et al., 2013) . Our data agree with the implication of reactive metabolites in the induction of hepatocellular injury. Indeed when CYP activities were inhibited by addition of the nonspecific CYP inhibitor ABT, toxicity was reduced. Importantly, SIT was approved for use in clinical trials at a daily dose of 100 mg and 300 mg/day and idiosyncratic hepatotoxicity is known to occur more frequently with drugs administered at >50 mg/day (de Abajo et al., 2004) .
In the 5-year EARLY study, 16.8% PAH patients treated with BOS showed elevation of transaminases superior to 3-fold the upper limit of normal, mostly within the first 6 months of treatment (Simonneau et al., 2014) . Bosentan was found to cause toxicity in primary human hepatocytes; it is a strong PXR activator (Weiss et al., 2013) and is mainly metabolized by CYP3A4 and CYP2C9 (Gatfield et al., 2012) into 4 metabolites. As expected, cotreatment with ABT also reduced its toxicity (Matsunaga et al., 2016) . Our data with HepaRG cells treated with ABT fully agrees with this study concluding that at least one BOS CYP-mediated metabolite is potentially hepatotoxic. Noticeably, because combined treatment with phosphodiesterase 5 inhibitors and other drugs is used for the treatment of PAH (Ghofrani et al., 2011) different interactions between BOS and other drugs could be expected to contribute to greater liver damage.
Contrary to BOS and SIT, AMB and MAC are not known to induce hepatocellular injury in man. In agreement with clinical data (Barst, 2007; Takatsuki et al., 2013) , AMB was not toxic to HepaRG cells. It is mainly metabolized by UGTs; only 20% undergoes oxidative metabolism via CYP3A4 and to a lesser extent CYP3A5 and CYP2C19 (Croxtall and Keam, 2008) . Noteworthy, AMB is used at 5 mg/day, a low concentration compared to other ERAs (Chaumais et al., 2015; Takatsuki et al., 2013) . Macitentan was cytotoxic to HepaRG cells but at higher concentrations than BOS (IC20 values: 230 vs 120 mM, respectively). Moreover, MAC toxicity was not reduced by a HepaRG cells were exposed to the 4 drugs at the indicated concentration (ie, 10, 50, or 100 mM) for 24 h. mRNA levels were measured by RT-PCR analysis. All results are expressed relative to the levels found in control cells, arbitrarily set at a value of 1. *P < .05 compared to untreated cells.
cotreatment with ABT, supporting that its toxicity was not CYPmediated. In agreement, although MAC is mainly metabolized by CYP3A4 and to a small extent by CYP2C8, CYP2C9, and CYP2C19 (Chaumais et al., 2015) it is well established that at a clinical relevant concentration, drug-drug interactions do not occur with coadministered drugs that are also substrates of CYP3A4 (Sidharta et al., 2015) . In HepaRG cells, MAC and BOS caused deformation of BC and impairment of MLC2 phosphorylation that have previously been found to be characteristics of cholestatic drugs Sharanek et al., 2016) (Table 3 ). Contrary to the two other ERAs, AMB and SIT, which exhibit different chemical structures and are specific for ET A receptors, MAC and BOS share a similar chemical structure (Supplementary Table 3 ) and reactivity with both ET A and ET B receptors. Macitentan and BOS structures differ only by addition of the replacement of the sulfonamide moiety by a smaller alkyl-sulfamide group in the former, resulting in an increased lipophilicity (Chaumais et al., 2015) .
Intrahepatic cholestasis is typically characterized by an inhibition of biliary efflux of BAs leading to their accumulation mostly in hepatocytes. As expected TCA and CDF efflux that reflects BSEP and MRP2 activity, respectively, was inhibited by both BOS and MAC, supporting a strong inhibition of canalicular efflux. These results as well as inhibition of NTCP agreed with several previous studies (Hartman et al., 2010; Lepist et al., 2014; Morgan et al., 2013) . However, some authors reported only weak inhibition if any, of BSEP with MAC (Treiber et al., 2007) and MRP2 with BOS (Hartman et al., 2010; Lepist et al., 2014) . These discrepancies likely reflect use of different experimental conditions. Such inhibitions of efflux and influx transporters are not specific of cholestatic drugs (Kö ck et al., 2014; Pedersen et al., 2013) . As observed earlier (Hartman et al., 2010; Kenna, 2014; Morgan et al., 2013) , SIT also inhibited TCA and CDF efflux activity in HepaRG cells. No BA accumulation was observed with any of the 4 ERAs in HepaRG cell cultures but on the contrary, total BAs content was decreased in cellular layers after 4 and 24 h treatment in a serum-free medium. A similar observation has been made by using sandwich-cultured human hepatocytes treated with these drugs (Lepist et al., 2014) . The decrease in total BAs content in cellular layers after treatment with BOS, MAC, and SIT could be related to MRP3 overexpression and consequently resulting in increased sinusoidal efflux. Multidrug resistance-associated protein 3 has been reported to be upregulated as a result of an adaptive mechanism to the inhibition of MRP2 and BSEP efflux (Donner and Keppler, 2001) , including in HepaRG cells KO in BSEP (Qiu et al., 2016) . Noticeably, a 2.5-fold activation of TCA efflux after 2 h with a low concentration of SIT (ie, 10 mM), which has been described for troglitazone, entacapone, or diclofenac (Al-Attrache et al., 2015.; Burbank et al., 2016) , was observed. An uncoupling effect between lipids and bile salt independent efflux at the MRP2 level has also been described in BOS-treated rats (Fouassier et al., 2002) . Whether a similar effect can occur in treated patients and in cultured human hepatocytes remains unknown.
Only BOS has been reported to cause some cases of cholestasis in clinic. Several explanations can be advanced to support the absence of reported clinical cases of cholestasis with MAC: (1) the approval of this drug received only in 2013 and consequently the limited number of patients treated to-date; (2) the different physico-chemical properties, pharmacokinetics, and metabolism profiles; (3) more likely conditions of administration to patients. Bosentan is dosed at 62.5 mg two times a day for 4 weeks before using a dose of 125 mg/day while MAC is active at 10 mg/day (Pulido et al., 2013) and has a lower C max in comparison with BOS; (4) its 15-fold increased receptor residence time (t 1/2 ) compared to BOS, that could explain at least partly its therapeutic effects at lower dosages (Gatfield et al., 2012) . Moreover, cholestatic features were obtained in vitro with BOS at lower concentrations (<100 mM) than with MAC. Noteworthy, an association of BOS and the direct ROCK inhibitor fasudil has been tested. Indeed, fasudil has been successfully used to reverse PAH findings in animal models (Liu et al., 2011) . However, no improvement of exercise capacity and pulmonary hemodynamics was evidenced after a 3-month treatment of PAH patients with fasudil (Fukumoto et al., 2013) . Moreover, our in vitro data showed that BOS-induced BC dilatation was strongly enhanced by coaddition of fasudil in HepaRG cells, suggesting that the combination of the two drugs could result in enhanced cholestatic effects ( Supplementary Fig. 4) .
In summary, our data demonstrate that the two ERAs, BOS, and MAC, share some typical cholestatic features which could be attributed to their similar chemical structures. However, these two drugs differ by several properties, in particular lower daily therapeutic dosages and C max , and longer receptor residence time that could explain the absence of MAC toxicity presently reported in patients. In addition, our results support a relationship between SIT and BOS hepatotoxicity and the formation of CYP-mediated reactive metabolites. They also support the current recommendation to monitor liver enzymes at the initiation of MAC treatment and in the presence of clinical findings, and to discontinue therapy if patients develop sustained aminotransferase and bilirubin elevations (Monaco and Davila, 2016) .
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